Sol-Gel Technologies Ltd.

SLGL

IL0011417206

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-01 pm EDT			5-day change	1st Jan Change
0.782 ^USD	+9.75%		-15.00%	-29.23%

Mar. 13	Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 29	Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director	CI

Sol-Gel Technologies Ltd. announced that it has received $10 million in funding from M. Arkin Dermatology Ltd.

April 18, 2023

On April 19, 2023, Sol-Gel Technologies Ltd. closed the transaction.

Latest news about Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director	Feb. 29	CI
Transcript : Sol-Gel Technologies Ltd. - Special Call	Dec. 06
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study	Nov. 30	CI
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board	Nov. 20	CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating	Nov. 13	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Adjusts Price Target on Sol-Gel Technologies to $12 From $19, Keeps Buy Rating	23-08-14	MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $7 From $9, Maintains Strong Buy Rating	23-08-11	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Sol-Gel Technologies Ltd. Appoints Sharon Kochan to the Board of Directors	23-07-27	CI
Raymond James Adjusts Sol-Gel Technologies' Price Target to $9 From $10, Keeps Strong Buy Rating	23-07-19	MT
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs	23-06-06	MT
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada	23-06-06	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Sol-Gel Technologies Ltd. announced that it has received $10 million in funding from M. Arkin Dermatology Ltd.	23-04-18	CI
Raymond James Adjusts Price Target on Sol-Gel Technologies to $10 From $13, Maintains Strong Buy Rating	23-03-14	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Transcript : Sol-Gel Technologies Ltd. - Special Call	23-01-27
Sol-Gel Technologies Launches $22.8 Million Registered Direct, Private Placement Offerings; Shares Drop Pre-Bell	23-01-27	MT
Sol-Gel Technologies Ltd. announced that it expects to receive $10 million in funding from M. Arkin Dermatology Ltd.	23-01-26	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
HC Wainwright Cuts Price Target on Sol-Gel Technologies to $19 From $22, Affirms Buy Rating	22-11-14	MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $13 From $16, Maintains Strong Buy Rating	22-11-11	MT

Chart Sol-Gel Technologies Ltd.

Duration

Period

More charts

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Companyâs offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sol-Gel Technologies Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7125 USD

Average target price

8 USD

Spread / Average Target

+1,022.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOL-GEL TECHNOLOGIES LTD.	-29.23%	19.85M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs